"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Descriptor ID |
D004317
|
MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
Concept/Terms |
Adriblastin- Adriblastin
- Adriblastine
- Adriblastina
- Adriablastine
- Adriablastin
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in this website by year, and whether "Doxorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2001 | 0 | 2 | 2 |
2006 | 0 | 1 | 1 |
2007 | 2 | 1 | 3 |
2010 | 1 | 1 | 2 |
2011 | 2 | 0 | 2 |
2012 | 0 | 3 | 3 |
2013 | 1 | 0 | 1 |
2014 | 1 | 0 | 1 |
2015 | 1 | 3 | 4 |
2016 | 2 | 2 | 4 |
2017 | 30 | 39 | 69 |
2018 | 31 | 31 | 62 |
2019 | 11 | 17 | 28 |
2020 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
Sialic acid-conjugate modified doxorubicin nanoplatform for treating neutrophil-related inflammation. J Control Release. 2021 09 10; 337:612-627.
-
Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy. J Allergy Clin Immunol. 2021 07; 148(1):91-95.
-
Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: A case report. Curr Probl Cancer. 2021 12; 45(6):100739.
-
SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study. Eur J Pharmacol. 2021 Apr 05; 896:173922.
-
Masquerading of COVID-19 Infection as Primary Mediastinal Large B-Cell Lymphoma Turk J Haematol. 2021 02 25; 38(1):77-78.
-
Phase I feasibility study of Magnetic Resonance guided High Intensity Focused Ultrasound-induced hyperthermia, Lyso-Thermosensitive Liposomal Doxorubicin and cyclophosphamide in de novo stage IV breast cancer patients: study protocol of the i-GO study. BMJ Open. 2020 11 26; 10(11):e040162.
-
Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak. Br J Haematol. 2020 11; 191(3):386-389.
-
Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study. Ann Hematol. 2020 Nov; 99(11):2589-2598.
-
Radical change in osteosarcoma surgical plan due to COVID-19 pandemic. BMJ Case Rep. 2020 Jul 08; 13(7).
-
Incidental COVID-19 in a heart-kidney transplant recipient with malnutrition and recurrent infections: Implications for the SARS-CoV-2 immune response. Transpl Infect Dis. 2020 Dec; 22(6):e13367.